Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...
American Council on Science and Health6d
“Rare” but Not Uncommon: The Hidden Crisis of Rare Diseases
Rare diseases - a medical condition so obscure that even your doctor has to Google. Despite their name, these diseases ...
CURE3d
Bexobrutideg Receives Orphan Drug Designation in Waldenström Macroglobulinemia
Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...
BioArctic receives Orphan Drug Designation for exidavnemab the US
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug ...
CURE3d
FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...
Aspen Daily News1dOpinion
National mesothelioma registry critical to advance research, treatment
After being used since the 1940s in various industries, asbestos is now linked to severe health risks, including asbestosis, ...
PharmiWeb2d
Evaluate Releases 2025 Orphan Drug Report
Evaluate, the leading provider of market insights for the pharmaceutical industry, today released its 2025 Orphan Drug Report highlighting forecasts for the orphan drug market out to 2030. The 2025 ...
pharmaphorum3d
The biggest challenges facing rare disease pharma – and how the industry can tackle them
As Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers and ask whether the future is bright or bleak for these difficult conditions.
Ophthalmology Times2d
HanAll Biopharma receives Orphan Drug Designation in Japan for Batoclimab for thyroid eye disease
Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).
pharmaphorum6d
Invitation to SMI’s Orphan Drugs & Rare Diseases Conference 2019
SMi reports: Invitation from conference co-chair released for the 9 th Annual Orphan Drugs & Rare Diseases conference, taking place in London this October In October, attendees will hear various ...